Deep Brain Stimulation Devices Market To Reach $2.50 Billion By 2030

Deep Brain Stimulation Devices Market Growth & Trends

The global deep brain stimulation devices market size is anticipated to reach USD 2.50 billion by 2030, according to a new report by Grand View Research, Inc., growing at a CAGR of 9.9% from 2023 to 2030. Growing awareness about deep brain stimulation therapy, a surge in the incidence of neurological disorders, and the introduction of technologically advanced productsdrive the growth of the market. An increase in FDA approvals for deep brain stimulation devices in clinical applications, such as tremors, severe obsessive-compulsive disorders, and dystonia, is further fueling the market growth. For instance, in December 2022, Nexstim Plc made a notable announcement regarding the sale of two NBT systems. These systems were acquired through Canadian Health Solutions (CHS), the company's distributor in Canada.

This development is expected to have a positive impact on the market's growth in the near future, signaling a growing demand for Nexstim's innovative solutions within the Canadian healthcare landscape. The incidence of neurological disorders such as epilepsy, Parkinson's disease, and depression is increasing globally, which is expected to positively impact the market growth. For instance, as per the Depression and Bipolar Support Alliance, about 17.3 million people in the U.S. are suffering from major depressive disorder. As a result, a large number of people suffering from such conditions & disorders is expected to boost the demand for DBS devices during the forecast period.

 Request a free sample copy or view report summary: Deep Brain Stimulation Devices Report

Deep Brain Stimulation Devices Market Report Highlights

• On the basis of product, the dual-channel segment dominated the market in 2022 with a share of 57.0%. The growing adoption of double-channel DBS devices for the treatment of numerous neurological disorders, such as dystonia, PD, Alzheimer’s, and epilepsy, is driving the segment growth

• The Parkinson’s disease application segment dominated the market in 2022 with a share of 65.0% owing to the rising prevalence of PD globally. According to a UCB report, around 100,000 people in Canada have PD at present and more than 6,600 new cases are diagnosed each year

• The hospitals end-use segment dominated the market in 2022 with a share of 51.7% owing to a surge in the prevalence of neurological disorders and a rise in the number of DBS surgeries performed in hospitals

• North America dominated the market with the highest revenue share of 51.2% in 2022. This is due to the availability of highly skilled physicians, the high prevalence of psychological disorders, and the rise in awareness about treatments in this continent

Deep Brain Stimulation Devices Market Segmentation

Grand View Research has segmented the global deep brain stimulation devices market on the basis of product, application, end-use, and region:

Deep Brain Stimulation Devices Product Outlook (Revenue, USD Million, 2018 - 2030)

• Single-channel

• Dual-channel

Deep Brain Stimulation Devices Application Outlook (Revenue, USD Million, 2018 - 2030)

• Pain Management

• Epilepsy

• Essential Tremor

• Obsessive-compulsive Disorder (OCD)

• Depression

• Dystonia

• Parkinson’s Disease

• Others

Deep Brain Stimulation Devices End-use (Revenue, USD Million, 2018 - 2030)

• Hospitals

• Neurology Clinics

• Ambulatory Surgical Centers

• Research Centers

Deep Brain Stimulation Devices Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Norway

  • Sweden

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Mexico

  • Brazil

  • Argentina

• Middle East & Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of Deep Brain Stimulation Devices Market

• Abbott (St. Jude medical)

• Medtronic

• Boston Scientific Corporation

• Aleva Neurotherapeutics

• Nexstim

• LivaNova PLC

• Neuropace Inc.